Our community narratives are driven by numbers and valuation.
Voyager Technologies owns a big bet on what comes after the International Space Station, and the market may still be treating it like a plain defense supplier. If Starlab stays on track, the business could shift toward steady “rent-like” income from customers in space—but delays or execution missteps could change the story.Read more
The toll booth on global debt. Any bond sold to regulated buyers needs a rating from a recognized agency, and Moody's is half of a duopoly whose position comes from a regulatory licence rather than product quality — which is why no third entrant has emerged in decades.Read more
A proposed tie-up between NextEra Energy and Dominion Energy could become a big “picks-and-shovels” play on the surge in power demand from AI data centers in Northern Virginia. The upside comes with real hurdles—like winning regulatory approval and managing debt—before any growth shows up for customers and shareholders.Read more
Southern Silver is trying to turn a large underground silver project in Mexico into a real mine, and the next round of drilling could make the early years look much stronger. The catch is that it still needs permits and major funding, so the path from promising deposit to steady production could get bumpy.Read more

Kodiak AI already runs fully driverless trucks for a paying customer in the Permian Basin, and the big question is whether it can scale that fleet fast enough before it needs to raise more money. If deployments accelerate, the business could start to look less like a risky concept and more like a real software-driven trucking service—but slow adoption or dilution could derail the story.Read more
The unglamorous silicon everything electrical depends on. TI's moat is manufacturing, not design: 300mm scale cost leadership, 100,000+ SKUs sold direct, product lifecycles measured in decades.Read more
SPX Technologies sits in a sweet spot of the fast-changing data-center world, as liquid cooling shifts spending from big chillers toward simpler outdoor heat-removal equipment. But a closer look shows parts of the business are slowing, recent deal-making adds complexity, and the stock price already assumes a lot goes right.Read more

Newron’s future now hinges on one late-stage drug being tested as an add-on for people with schizophrenia who don’t respond well to current treatments, setting up a make-or-break moment when results arrive. The company has lined up extra funding, longer patent protection, and an active partner in Asia—but if the trial disappoints, there’s little else to fall back on.Read more